← All trials
NCT07261241
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2026
- Primary completion
- Jul 31, 2030
- Completion date
- Jul 31, 2031
- First posted
- Dec 3, 2025
- Last posted
- Dec 3, 2025
- Enrollment
- 118
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- Jubilant DraxImage Inc.Collaborator
- United TherapeuticsCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.